American Workers Assess an Economic Disaster

Nearly three years into a devastating economic recession, American workers are deeply pessimistic about prospects for economic recovery. The majority believe that the nationas economy has undergone a fundamental and lasting change, according to American Workers Assess an Economic Disaster, a new nationwide Work Trends survey from the Heldrich Center.Some of the key findings of the national survey are:Nearly three in four (73%) Americans have been directly affected by a recession that is unprecedented in its length and severity. Nearly two in three of those surveyed expect the United States to still be in a recession next year; another 18% fear a depression is coming. More than half (56%) think the U.S. economy has undergone a fundamental and lasting change as opposed to a temporary downturn (43%). Fully 41% anticipate that the United States will be experiencing similar economic conditions a year from now while another quarter (27%) actually believes the economy will get worse before it gets better. Nearly 9 in 10 Americans (86%) who are still working express at least some concern about their job security; half of them report being very concerned

Project Brainstorm: Using Neuroscience to Connect College Students with Local Schools

Neuroscience can be used as a tool to inspire an interest in science in school children as well as to provide teaching experience to college students

Review: Hepatitis C Protease and Polymerase Inhibitors in Development

Hepatitis C infection (HCV) remains a global problem and the current anti-HCV therapies available in the clinic have sustained virologic response rates (SVR) of only about 50%, especially in HCV genotype 1–infected subjects. The SVR is even lower in HIV-HCV co-infected patients, estimated at only about 30–40%. However, exciting new research is under way to find new anti-HCV therapies. Presently, efforts to develop new anti-HCV agents for HCV-infected persons who fail pegylated interferon and ribavirin-based therapies have focused on inhibitors of key HCV enzymes such as the HCV NS3 protease and the NS5B polymerase. There are two protease inhibitors, telaprevir (VX-950, Vertex) and boceprevir (SCH 503034, Schering-Plough); and three polymerase inhibitors, valopicitabine (NM283, Idenix), R1626 (Roche), and HCV-796 (Viropharma) that have advanced to late-stage clinical trials. Of these aforementioned agents, telaprevir is the most advanced in clinical development. Early trial results on efficacy, safety, and HCV drug-resistance profiles of these novel agents will be discussed in this review paper

Response-guided telaprevir combination treatment for hepatitis C virus infection.

Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 weeks of peginterferon-ribavirin treatment for a sustained virologic response. We designed a noninferiority trial (noninferiority margin, -10.5%) to compare rates of sustained virologic response among patients receiving two treatment durations